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ABSTRACT
14-3-3ζ Regulation of Metastasis Through Mediation of Liprin-α and Liprin-β
Rachel Hynes
Department of Chemistry and Biochemistry, BYU
Master of Science
Cancer is a set of varied and diverse diseases that share common characteristics, such as
active proliferation, increased replicative potential, and tissue invasion or metastasis. One
protein, 14-3-3ζ, is shown to be upregulated in a number of different cancers and also correlates
with poor patient prognosis, recurrence, and mortality. This protein comes from a family of
adapter proteins known for their scaffolding ability, pro- and anti-oncogenic capabilities, and
affinity for phosphorylated substrates. It has been shown previously to participate in cancer
progression, subversion of apoptosis, and to increase chemoresistance. Herein we will discuss
the ability of 14-3-3ζ to promote distant-site metastasis and we propose that it does so through a
variety of different mechanisms including the MAPK signaling cascade, HER2/ErbB2 pathway,
and by mediation of cell adhesion through regulation of LAR.
Liprin-β was identified as a novel 14-3-3ζ interactor in a mass spectrometry-based
interactomics analysis. 14-3-3ζ was found to co-immunoprecipitate with both Liprin-α and
Liprin-β. We will discuss the identification and mutation of putative 14-3-3ζ binding sites on
both Liprins, the effect these have on the binding of both Liprins to 14-3-3ζ and of Liprin-α to
LAR, and the possible downstream consequences of these interactions. The results described
herein are inconclusive due in part to our inability to obtain a reliable Liprin-β pulldown and in
part our inability to identify the 14-3-3ζ-binding sites on Liprin-α and Liprin-β. The concluding
chapter contains a discussion of the possible future directions, including the creation of further
Liprin mutants as well as fluorescent imaging of LAR localization and focal adhesion turnover.
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INTRODUCTION

Background on Cancer and Metastasis
Cancer is a set of diseases caused by mutations in the genetic code that vary by type,
location, cause, effect on genetic expression, and drug resistance. Despite these differences, all
cancers share six common traits: apoptosis resistance, limitless replicative potential, active
proliferation, induced angiogenesis, suppression of growth inhibitors, and tissue invasion and
metastasis.1-2 As with the origin of cancer, the cause of each of these traits varies from one type
of cancer to another. In fact, even patients diagnosed with the same type of cancer frequently
have tumors that are genetically and phenotypically different. With respect to biomedical
research, each trait represents a convoluted puzzle with multiple starting points and many
different overlapping and crisscrossing paths, all producing similar outcomes. One of the most
intriguing cancer trait puzzles is deciphering how these cells develop the ability to migrate from
the site of the original tumor to a distant, noncancerous tissue and give rise to a new tumor.
Metastasis, or the process by which cancerous cells spread from the original tumor to a
new site, occurs in nearly all late stage cancers and results in poor prognosis.1, 3-4 The correlation
between metastatic cancer and patient mortality originates from the increased likelihood of
cancer recurrence upon formation of secondary tumors. This harmful process of recurrence at a
secondary site can occur immediately or even years after removal of the original tumor.
Metastasis plays a leading role in cancer progression, chemoresistance, patient mortality, and has
1

been reported to be the cause of 90% of solid tumor deaths.5 Many labs and clinics across the
world are researching how metastasis occurs in the various types of cancer. Despite the amount
of research taking place, the causes and mechanisms have not yet been completely elucidated
and metastatic tumors still develop.
No single cause of metastasis exists, but it occurs when a tumor cell retracts the focal
adhesions (FAs) that anchor it the extracellular matrix (ECM) and adherent junctions (AJs) that
link to the surrounding cells and then proceeds to migrate through the bloodstream or lymphatic
vessels until it rests at a site distant from the primary tumor.6 Once the cell settles, it can remain
dormant or immediately begin proliferating to form another tumor. This type of invasive cancer
is hard to detect and difficult to eradicate because physicians cannot always predict the location
of secondary tumor growth and the dormant tumors often remain too small to be identified until
after removal of the original tumor. The ability of these cells to evade detection and the
detrimental effects of systemic cancer treatment on the patient make evident the necessity of
further research to better understand the mechanisms through which tumor cells undergo
metastatic transition.
There are many different signaling pathways that lead to metastasis. Nearly every type of
cancer employs a distinct pathway to initiate tumor cell metastasis, making the task of finding
the cause a daunting undertaking, especially considering that no single cause exists. However,
despite their differences many types of cancer share characteristics such as proteins expressed or
genes silenced. Similarities such as these aid in the study of tumor cell metastasis because the
study of one type of cancer can correlate to other types. One such family of proteins that is
differentially expressed in multiple types of cancers is the 14-3-3 family. Recently, their relation
to cancer has been increasingly studied. They are known to interact with a myriad of proteins
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involved in a variety of different cellular functions, many of which pertain to cancer progression
and growth and others to cancer evasion. In this review, we focus on elucidating the role of one
member of the family, 14-3-3ζ, and how its overexpression leads to cancer metastasis.

Defining 14-3-3 Proteins
Though originally isolated from brain tissue in 1967,7 the 14-3-3 proteins can be found in
a number of organs and tissues throughout all eukaryotic organisms.8 The name of these proteins
comes from the fraction containing the proteins collected after filtration by DEAE column
chromatography.9 The 14-3-3 proteins are a conserved family of acidic proteins made up of
seven different isoforms (β, γ, ε, ζ, η, σ, and τ) encoded by different genes which can be found in
all eukaryotic organisms.8 Through interactions with a variety of different proteins, 14-3-3
participates in a number of cellular functions, including cell cycle progression, cell survival,10-11
metabolism,12 protein trafficking,13 and signal transduction.10, 13-22
14-3-3 family proteins participate in hundreds of different pathways and interactions,
despite having no inherent enzymatic activity. Instead they function by first dimerizing then
interacting with and modulating the activity of other proteins in a phosphorylation-dependent
manner.23 The phosphorylated interacting partners contain conserved binding motifs, the most
common of which is RXXpS/TXP, where pS/T represents the phosphoserine/threonine to which
14-3-3 proteins directly bind.24 Regulation on a given protein by 14-3-3 can cause scaffold-like
activity, sequestration, activation or inhibition, conformational change, or complex formation.
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14-3-3 Proteins and Cancer
In general, members of the 14-3-3 family are somewhat polarized when it comes to their
role in cancer: for example, the sigma isoform generally acts in a tumor suppressor role while
many of the other isoforms have pro-oncogenic effects. Some studies show, however, that this
division is not as black and white as it first appears and that certain isoforms can play both proand anti-oncogenic roles depending on the expression level and profile.25-27 The 14-3-3 family of
proteins has been shown to play a role in almost every type of cancer (reviewed in reference 23).
Each 14-3-3 dimer pair (including homo- and heterodimerizations) has a unique set of binding
partners with few overlapping interactors, which results in each set having a distinct impact on
cancer.28-30 Many of these interacting partners participate either directly or indirectly in cancer
progression. For example, interaction with BAD, Cdc25, and β-integrins leads to their altered
localization; binding to Raf-1, CHK1, WEE1, and serotonin-N-acetyl transferase alters their
enzymatic function; finally, binding to proteins such as RAF-BCR and RAF-A20 causes
complex formation.10, 31-38 14-3-3 proteins also interact with the type 1 insulin-like growth factor
receptor (IGFIR), a protein that regulates growth and development upon binding of either IGF-I
or IGF-II in both normal and cancerous cells.39 Binding of 14-3-3 to IGFIR induces cancer cell
transformation, whereas blocking 14-3-3 binding to IGFIR by mutation causes the cells to lose
the ability to form soft agar colonies.40
The zeta isoform of the 14-3-3 family has been shown to correlate with multiple types of
cancer, including colon,41 lung,42-43 stomach,44 and breast cancer.45-47 In breast cancer
specifically, the overexpression of 14-3-3ζ has been linked to poor patient prognosis, patient
mortality, increased recurrence, and greater chemoresistance.48-51 Many studies suggest that 143-3ζ plays a role in transformation, cancer progression, tumor cell survival, invasion, and has
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been well characterized as an inhibitor of apoptosis. It is known to aid in cell survival by
interacting with a network of proteins involved in apoptosis, including BAD, Bax, caspase-2, and
Raf kinases.52 Subversion of apoptosis allows cancerous cells to grow under conditions that
would normally cause cell death, such as limited nutrient and oxygen supply or high levels of
genetic mutations.
In addition to subversion of apoptosis, 14-3-3ζ also participates in various stages of
tumor growth. This can be seen by observing the effects of 14-3-3ζ in different cancers and how
they related to the hallmarks of cancer: replicative potential, apoptosis resistance, proliferation,
angiogenesis, suppressed growth inhibitors, and invasiveness. In human esophageal cancer, 14-33ζ expression is associated with tumorigenesis.53 In breast cancer, 14-3-3ζ overexpression
inhibited apoptosis.54 In prostate cancer it activates proliferation through association with the
androgen receptor in the nucleus.55 In multiple myeloma, siRNA knockdown of 14-3-3ζ caused a
downregulation of various functions related to angiogenesis.56 In transformed oncogenic mouse
mammary epithelial cells, 14-3-3ζ was shown to have an opposing role to 14-3-3σ and
stimulated growth by negatively modulating TGF-β1 growth inhibition.57 In intrahepatic
cholangiocarcinoma (ICC) it enhanced the tumor cell invasiveness as well as increasing their
proliferative capacity.58 Considering these data, 14-3-3ζ likely acts as a coordinator for the
various stages and pathways involved in cancer development and progression.

14-3-3ζ and Metastasis
The ability of 14-3-3ζ to induce apoptosis has been researched extensively, while its role
in cell adhesion and motility is not as well understood. 14-3-3ζ, as with all the 14-3-3 family
proteins, is generally known as a scaffolding protein, though it can also act to sequester,
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activate/inactivate, or induce conformational changes as previously mentioned. Many of the
signaling pathways that 14-3-3ζ participates in and proteins it has been shown to interact with
take part in cancer, specifically in cancer metastasis. It has been shown to increase distant site
metastasis, cancer recurrence, and increased invasion in multiple types of cancer, including
breast, lung, esophageal, ICC, and colon. Here we will discuss a few of the different metastasispromoting pathways and proteins that 14-3-3ζ interacts with, including MAP kinase cascade
signaling, HER2/ErbB2 pathway, and LAR-mediated cell adhesion.

1.4.1

MAP Kinase Signaling Cascade
In order for a tumor cell to initiate metastasis it must undergo a series of events leading to

its retraction from the surrounding tissue and survival in the vasculature until it reaches its target
tissue. This involves the integration of many different signaling pathways, one of which is the
mitogen-activated protein kinase (MAPK) cascade. MAPK signaling is a complex network of
interconnected pathways that can lead to initiation of many of the steps leading to metastasis.
The following paragraphs will discuss the role of MAPK in the epithelial mesenchymal
transition (EMT), apoptosis evasion, survival in the vasculature, and initiation of the dormancy
stage.
First, the cells must undergo EMT in order to allow them to migrate and invade other
tissues.59 EMT can be induced through various methods, many of which pertain to MAPK and its
associated proteins. One such method involves a coordinated effort of transcription factors such
as Twist1, Snail, and Slug, that repress e-cadherins, allowing the cell to release its FAs and AJs
in order to move away from the surrounding tissue.59 EMT has been shown to be initiated by
direct regulation of these transcription factors or indirectly through reactive oxygen species
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(ROS). MAPK-associated proteins have been shown to respond to ROS accumulation in the
context of tumor invasiveness and correlate with the expression of both Twist1 and Snail.60-62 A
second method of coordinating the transcription factors is through TGF-β4 which has been
shown to be induced by MAPK signaling and to lead to EMT.63 Lastly, EMT can be induced by
hypoxia, a condition common to tumor cells that grow to a size exceeding the limit of nutrient
and oxygen delivery. Furthermore, one of the key transcription factors induced by hypoxia, HIF1α, is stabilized by the p38α MAPK, which is sufficient to directly activate Snail and Twist.64
Second, the cells that release from their surrounding tissue must circumvent apoptosis
while they undergo circulation until they reach the target tissue. In order to prevent the spread of
tumors, cells have developed a mechanism to induce apoptosis in cells that release their FAs.
This process of anoikis, or anchorage-dependent apoptosis, must be overcome by tumors in order
for them to survive once they release from the primary tumor. Interestingly, the suppression of
components of the MAPK cascade has been linked to tumor suppression by inducing anoikis and
inhibition of these MAPK proteins induces anoikis resistance.65-67 This seemingly opposing role
of MAPK signaling in cancer progression illustrates the need for tight regulation of the MAPK
cascade, possibly through a scaffolding protein such as 14-3-3ζ. 14-3-3 could potentially cause a
tumor cell to release from the primary tumor by activating the MAPK signaling pathway, but
then through sequential inactivation, prevent the pathway from inducing apoptosis.
Third, the cancer cells that successfully release from the tumor and survive the transition
to mesenchymal cells must enter the blood stream or lymphatic system by degrading the
extracellular matrix (ECM). MAPK signaling cascade phosphorylates heat-shock protein 27 to
activate its anti-apoptotic and pro-metastatic role in cancer.68 In order to become invasive cells
must become motile, a process that involves the coordination of FA removal and placement as

7

well as actin polymerization and depolymerization. MAP kinase activity inactivates the actin
depolymerizing factor cofilin by phosphorylation, allowing the actin filaments to polymerize and
carry out cell motility. 68 Knockdown of MAPK proteins by dominant-negative mutants and
siRNA inhibition caused a decrease in cell invasion.69-73 MAPK modulates the activity of
urokinase-type plasminogen activator, uPA, which plays a critical role in the invasion,
intravasation, and metastasis.74-75
Lastly, once the cells reach the new tissue and before they begin infiltrating and forming
a new tumor, the cells generally enter a dormancy stage called metastatic latency.76 This stage of
latency occurs after a cell reaches the target organ and before it receives the proper signals to
begin rapid proliferation. Generally, cells accomplish this by arresting the cell cycle at the G0/G1
stage or by equalizing the rate of proliferation and death.77 Extracellular signals cause the
inactivation of ERK1/2 and activation of p38MAPKs resulting in dormancy stage, while reversal
of these two opposing states initiates rapid tumor growth of a distant, metastatic tumor.76
As shown above, the MAPK cascade participates in many of the steps necessary for a cell to
become metastatic. Some of its key regulators, such as the proteins Ras, Raf and mitogenactivated protein kinase kinase (MEK), belong to the family of 14-3-3ζ-interacting proteins.78-80
The presence of 14-3-3ζ has been shown to be sufficient and necessary for activation of the
MAPK/ERK (extracellular signal-regulated kinase) pathway and overexpression of a
dominant/negative 14-3-3ζ mutant resulted in p38/MAPK activation and apoptosis induction.60,
79, 81

These results indicate that 14-3-3ζ acts as a regulator between the MAPK-associated p38

and ERK pathways in order to promote cell survival and metastasis. A second method of 14-3-3ζ
activation of the MAPK/ERK cascade is by binding and activating c-Raf.82 Activation of this
part of the MAPK signal cascade by 14-3-3ζ could lead to MAPK-induced metastasis.83
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Thymosin β4, another known regulator of the MAPK cascade, initiates its
phosphorylation-dependent activation.84 While no direct correlation between 14-3-3ζ and
thymosin β4 has been experimentally proven, both proteins have been shown to correlate with
the metastatic potential of tumor cells via MAPK signalling.85 These two proteins, Thymosin β4
and 14-3-3ζ, likely work in conjunction to regulate this pathway

1.4.2

HER2 Pathway
Human epidermal growth factor receptor 2 (HER2), also known as receptor tyrosine-

protein kinase ErbB2, belongs to the human epidermal growth factor receptor tyrosine kinase
(RTK) family along with EGFR, ErbB3, and ErbB4. The overexpression of these proteins has
been shown to play a role in malignant cancer progression and each are targets for many anticancer therapies.86-87 Interestingly, HER2 has no known ligand but is still crucial to downstream
RTK signaling by forming heterodimers with its sister proteins.88 Each of these receptors can be
activated by ligand-binding or in a ligand-independent manner in response to phosphorylation
induced by ionizing radiation (IR).89-92 Oxidative stressors, such as IR exposure, lead to
tumorigenicity and increased invasion of tumor cells into the surrounding tissue.93-95 The HER2
protein is overexpressed in 20% of breast cancers and, like 14-3-3ζ, correlates with poor patient
prognosis, and increased levels of metastatic cancer.96-99 Similarly to HER2, 14-3-3ζ has been
found to be expressed in early stage tumors, to correlate to poor patient prognosis, and to have
IR-mediated overexpression. One study showed that both HER2 and 14-3-3ζ signaling increase
upon IR activation to promote breast cancer metastasis.100
As with most cancers, breast cancer progresses through various stages, including invasive
breast cancer (IBC) and its noninvasive precursor ductal carcinomas in situ (DCIS). While highly
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expressed in DCIS cells, the protein HER2 is found in only approximately 25% of IBC cases.87,
101-103

These statistics indicate that HER2 expression alone is insufficient to promote the

transition from DCIS to the invasive, more lethal form of breast cancer. The question remains as
to what cofactor acts in conjunction with HER2 to initiate the transition to metastatic cancer.
Though many different candidate proteins or other metastasis-promoting factors could aid in the
transition from DCIS to IBC, we propose that this is accomplished through coordinated signaling
with 14-3-3ζ.
The protein 14-3-3ζ, as previously discussed, binds to many different proteins that
influence the various hallmarks of cancer.1, 10, 16 Furthermore, 14-3-3ζ was found to be
overexpressed in many early stage breast cancer tumors, including DCIS.104 A recent study
looked at 14-3-3ζ overexpression in conjunction with HER2 in order to determine whether they
work in a cooperative fashion. The data showed that the co-overexpression of 14-3-3ζ and HER2
in in vitro breast cancer systems led to increased progression to IBC and higher levels of distant
site metastasis in mouse models.50 Though the exact mechanism of HER2-induced metastasis in
cancer cells remains unclear, it has repeatedly been shown to correlate with increased metastasis
and poor patient prognosis. While breast cancer patients testing positive for either HER2 or 14-33ζ showed increased likelihood of metastasis, those overexpressing both proteins have a
statistically higher likelihood of developing metastatic recurrence. The close correlation between
these two proteins and metastasis suggests that the HER2 and 14-3-3ζ pathways do not work in
parallel, but work in a convergent manner to promote metastasis (Figure 1).
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Figure 1 HER2 and 1414-3-3ζ work together to promote tumor cell metastasis.
Previously it has been proposed that HER2 and 14-3-3ζ work in either a sequential or
parallel pathway. We propose that they work together in separate but convergent pathways
to promote metastasis.

1.4.3

LAR-Mediated Adhesion
The protein-tyrosine phosphatase family is divided into two groups, or subfamilies,

consisting of receptor-like (RPTP) and nonreceptor PTPases, which function by
dephosphorylating tyrosyl-phosphorylated proteins.105-106 Like other RPTPs, leukocyte common
antigen related receptor (LAR) possesses a single transmembrane domain and two intracellular
phosphatase domains named D1 and D2.106-107 Unlike most receptors, ligand binding to RPTPs
typically causes their inactivation by inducing dimerization which allosterically inhibits the
active D1 domain through occlusions by the D1 domain of the opposing subunit.108-112 The D1
domain is believed to carry out the PTPase activity while the D2 domain typically remains
inactive, but plays a key regulatory role in determining substrate specificity.110, 113-116 Regulation
of the D2 domain occurs through the binding of various proteins, such as the scaffolding protein
called Liprin-α which is believed to influence LAR’s substrate specifity.117
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A recent 14-3-3ζ interactomics study revealed several novel 14-3-3ζ binding partners
including a metastasis-regulating protein called Liprin-β.118-119 Liprins comprise a gene family
that contains six Liprin-α and two Liprin-β proteins: α1, α2, α3, α4, β1, and β2. This highly
conserved family of scaffold proteins was originally identified as interacting partners of LAR in
1998.117 Since that time, many articles have been published about the binding partners and roles
of Liprins in cell migration and adhesion, synapse activity and development, and lymphatic
vessel development.120-129 Though little is known about the regulation of Liprins, their general
structure has been well characterized. Each Liprin protein contains a C-terminal liprin homology
(LH) domain comprised of three sterile alpha motif (SAM) domains and an N-terminal coiledcoil region.130 Liprin-α proteins heterodimerize and interact with a variety of different synaptic
proteins (CAST, GIT1, RIM, and KIF1A) via interaction at the SAM domain.129, 131-133 Though
the mechanism is still not well understood, Liprin-β and Liprin-α heterodimerize by binding at
the coiled-coil N-termini,117 an interaction that could lead to the Liprin-dependent activation of
LAR by 14-3-3ζ, causing a downstream effect of loss of cell adhesion through indirect
interaction with integrins.
Receptor tyrosine kinases (RTKs), the counterpart to RPTPs, act in a manner distinct to
that of RPTPs and are activated through ligand-induced dimerization, whereupon each subunit
participates in a trans-phosphorylation of tyrosine residues on the opposing receptor.134 RTKs
require a triple phosphorylation in order to remain fully active and often are inactivated through
dephosphorylation by either a nonreceptor PTPase or an RPTP. One such RTK substrate of the
LAR PTPase is Ephrin type-A receptor 2 (EphA2),135 also known as epithelial-cell kinase (Eck),
which is a member of the largest family of RTKs.136 Like the other 13 members of the Ephrin
family, EphA2 is membrane-bound and activated by ligands called ephrins, specifically ephrin-
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A. It is believed that the Eph-ephrin interaction and signaling cascade participate in cell motility
by limiting migration through inhibition of integrin-mediated adhesion and spreading, thus
obstructing migration.137-140
We propose that 14-3-3ζ overexpression initiates metastasis by interacting with a Liprinα/Liprin-β heterodimer, which in turn binds to LAR. This interaction recruits LAR to the cell
periphery where it can dephosphorylate EphA2, thus inactivating its ability to stabilize integrins
and FAs at the cell surface. In turn, this triggers the uptake of FAs into the cell causing a loss of
adhesion with the surrounding tissue and ECM, whereupon the cell is free to mobilize and
metastasize to a secondary site within the organism (Figure 2).
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Figure 2 Proposed mechanism of 14-3-3ζ/LAR-induced cell motility.
Overexpressed 14-3-3ζ interacts with Liprins, causing them to interact with
LAR and localize to the cell periphery. Once at the cell edge, LAR
dephosphorylates and inactivates EphA2, a RTK known to stabilize
integrins and inhibit cell motility. Upon EphA2 inactivation, the FAs are
internalized, leaving the cell free to migrate or metastasize.
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2

LIPRINS

Why Liprins
Liprins belong to a family of proteins known as the LAR protein tyrosine phosphatase
(PTP)-interacting protein family. This family consists of six proteins split into two distinct
classes, α and β. Four Liprin-α and two Liprin-β proteins have been identified in mammals: α1,
α2, α3, α4, β1, and β2. Each protein within the family is composed of an N-terminal coiled-coil
and a C-terminal liprin homology (LH) domain containing three sterile alpha motif (SAM)
regions (Figure 3). The Liprin proteins have been shown to homodimerize with proteins of the
same class (i.e. α to α or β to β) at their N-terminal coiled coil region and heterodimerize with
Liprins of the opposite class (α to β) or interact with other proteins at their C-terminal LH
domain.117, 124 Although substantial progress has been made toward understanding the
mechanism of Liprin-α signaling and its participation in cell adhesion, elucidation of the role of
Liprin-β and understanding how it participates in Liprin-α-mediated mechanisms remains an
active, though challenging, area of investigation.

Figure 3 Diagram of Liprin structure. C-terminal
coiled-coil domain where Liprins form homodimers.
N-terminal Liprin homology (LH) domain of three
sterile alpha motifs where Liprins form heterodimers
or bind to other proteins.
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2.1.1

Liprin-α
Liprin-α, also known as LAR interacting protein alpha (PTPRF interacting protein alpha

[PPFIA]), plays an integral role in synaptic vesicle trafficking and synapse development and
maintenance.123, 141 Liprin-α proteins bind a number of neuronal proteins, such as GRIP and
GIT1, through which they are suspected to coordinate trafficking of proteins like the AMPA
receptor in the active zone of synapses.127, 131 More recently the Liprin-α-GIT1 interaction has
been implicated as a positive regulator of motility by preventing the negative regulation of GIT1
on paxillin, a crucial component of FAs.142
A second regulatory role of Liprin-α on cell motility involves its effect on the
permanence of integrins at the cell surface. Integrins stabilize the actively proliferating actin
lamellipodia of migrating cells by anchoring the cytoskeleton to the extracellular matrix.143 A
2010 study identified Liprin-α as a factor that aids in the stabilization of β1 integrins by
preventing their internalization.119 Additionally, Liprin-α1 knockdown was shown to suppress
cell spreading and migration, whereas its overexpression promoted cell motility.126 It was also
shown to affect integrin distribution, alter cell morphology, enhance lamellipodia formation, and
increase spreading.118
Cell motility plays a key role in metastasis, and Liprin-α proteins have also been shown
to participate in the motility of cancer cells. The Liprin-α gene was shown to be amplified in
about 20% of breast cancers and correlating high protein expression was observed.144 The
researchers further identified Liprin-α as a novel regulator of tumor cell invasiveness and
metastasis in breast cancer cells.144 One way through which Liprin-α proteins affect motility is
by interacting with the distal phosphatase domain of LAR and increasing its trafficking to the
plasma membrane. Both Liprin-α and LAR have been found to localize to FAs at the cell
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periphery and initiate their disassembly and internalization, providing a means through which
cells can metastasize.126

2.1.2

Liprin-β
Liprin-β, also known as LAR interacting protein binding protein β (PTPRF interacting

protein binding protein [PPFIBP]), does not directly interact with LAR, but associates with it
though interaction with Liprin-α. Other than Liprin-α only one protein interactor has been
identified: a metastasis regulating protein named S100A4.145 As with α-Liprins, the β subfamily
sequence identity is highly conserved across species, suggesting a conserved evolutionary role
for both of these proteins. For the most part, the physiological role that Liprin-β proteins play in
cells has not been well studied,117, 145 though they were identified as a potential mediator of
lymphatic vessel integrity, specifically in intestinal lymphatic endothelial cells.146
Of the little that is known about Liprin-β, the majority of it shows a strong correlation
between this protein and cell motility. It is known to associate directly with Liprin-α and
indirectly with LAR, both of which regulate FA and/or AJ stability. Additionally, the study that
identified Liprin-β as a S100A4 interactor carried out immunofluorescent staining that revealed
enhanced Liprin-β1 staining at the cell periphery, predominantly at lamellipodia-like areas of the
membrane.145 Conversely, Liprin-β2 has been identified as a suppressor of motility. Knockdown
of ERK2 in invasive breast cancer cells resulted in the indirect upregulation of Liprin-β2 which
lead to the inhibition of motility.147 Together these data suggest that Liprin-β is highly dynamic
and careful regulation of the different isomers is required for regulation of metastasis. Such
intense regulation could be carried out via a scaffolding protein such as 14-3-3ζ.
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2.1.3

14-3-3ζ Interactomics
Overexpression of the protein 14-3-3ζ in breast cancer tumors has been identified as a

marker for poor patient prognosis and increased chemoresistance.23, 43, 51, 148 One method through
which 14-3-3ζ promotes cancer cell survival and chemoresistance comes from the ability of this
protein to aid in the subversion of apoptosis through the regulation and expression of proteins
such as Bcl-xL, Mcl-1, and Caveolin-1, and 14-3-3ζ.149 Other known binding partners of 14-3-3ζ
include Atg9,150 the Bcl2 family protein Bad, and Raf kinases. Given the chemoresistancepromoting nature of 14-3-3ζ and its phosphorylation-dependency, an interactomics study can be
used as a tool to identify novel phosphorylation-mediated interactions that regulate cancer cell
movement and survival.
Considering the cancer-promoting role of 14-3-3ζ, we can utilize a mass spectrometrybased analysis of the protein-protein interactions to identify possible mechanisms of 14-3-3ζinduced metastasis and chemoresistance. Often 14-3-3ζ is considered a scaffolding protein
because it has no inherent activity. Instead it relies on its interactions with phosphorylated
serine/threonine motifs on its binding partners in order to have an effect within the cell. Using
this interactomics tool, we can identify novel binding partners in order to determine the possible
effects of 14-3-3ζ on the cells.
Our recent mass spectrometry (MS)-based 14-3-3ζ interactomics work revealed a number
of new interacting partners including the metastasis-regulating protein called Liprin-β.118-119 The
ability of 14-3-3ζ to bind to Liprin-β is particularly interesting because very little is known about
the Liprin family of proteins, in particular Liprin-β. One particularly concerning effect of 14-3-3ζ
on cancerous cells is its ability to aid tumors in developing invasive cells,50 which increases the
risk of cancer recurrence and chemoresistance. While 14-3-3ζ is known to increase the
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occurrence of metastasis, the exact mechanism by which it does so remains unknown. One
possible method of promoting cell motility is through its interaction with Liprins.

2.1.4

Workflow
Many questions arise from the aforementioned information about Liprins and 14-3-3

proteins. Foremost among these questions is how does 14-3-3ζ induce tumor cell metastasis? To
better understand this, we must discover how 14-3-3ζ interacts with Liprins and the mechanism
by which this interaction induces motility and metastasis. The data discussed in this chapter will
be examined according to the following workflow (Figure 4).

Validation of the Interactomics Data
14-3-3ζ interacts with many different proteins, as discussed previously, and can have a
variety of functions, the primary one being scaffolding. Considering that 14-3-3ζ binds with such
specificity, the overexpression of 14-3-3ζ has been linked to poor patient prognosis, many
different proteins in the cell, a conclusive co-immunoprecipitation is difficult to obtain. In order
to validate the interactomics data, we overexpressed tagged Liprin constructs in HEK 293 cells
and ran an immunoprecipitation/Western Blot analysis to determine whether they pull down 143-3ζ.

2.2.1

Liprin-α Co-Immunoprecipitation
As described above, the interactomics study revealed that 14-3-3ζ binds to Liprin-β,

which is known to interact with Liprin-α. In order to determine whether Liprin-α also interacts
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Figure 4 Workflow of the experimentation and results discussed in this
chapter. Together with a proteomic analysis showing an interaction between
14-3-3ζ and Liprin-β, the question “How does 14-3-3ζ mediate metastasis?”
leads to further research into the exact method of protein binding and the
mechanism through which it promotes metastasis.

with 14-3-3ζ, we immunoprecipitated overexpressed Liprin-α-FLAG from transfected HEK 293
cell extracts and ran a Western blot analysis and blotted for 14-3-3ζ as well as LAR and Liprin-β.
The results show that 14-3-3ζ and endogenous Liprin-β will co-immunoprecipitate (co-IP) with
overexpressed Liprin-α (Figure 5). This does not, however, indicate a direct interaction between
14-3-3ζ and Liprin-α, the two could be linked by complex formation with Liprin-β.
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Figure 5 14-3-3ζ co-immunoprecipitates
with Liprin-α. HEK 293 cells expressing
Liprin-α-FLAG were immunoprecipitated
with anti-FLAG agarose beads and the
bound proteins visualized through Western
blot analysis. Cells treated with Liprin-αFLAG (lane 4) showed an increase in 143-3ζ pulldown when compared to the
untreated control (lane 3). As has been
shown previously, Liprin-β also
immunoprecipitates with tagged Liprin-α.

2.2.2

Liprin-β Plasmid Construction
The untagged Liprin-β construct was originally in a vector that only expresses in low

levels in both prokaryotic and eukaryotic cells. Bacterial transformations and HEK 293 cotransfections with this plasmid showed no expression of Liprin-β. In order to use the Liprin-β
construct we needed to add a tag for immunoprecipitation and clone it into a eukaryotic
expression vector. We did this in two steps: first we added an N-terminal Myc tag using the
“Myc add” forward and reverse primers (Table 1).
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Table 1: Liprin-β Myc-Tag and Restriction Site Addition Primers
Primer
Myc add_F
Myc add_R
LipB_RE BamHI_F
LipB_RE EcoRV_R
Myc del_F
Myc del_R
Myc C-term add_F
Myc C-term add_R

2.2.3

Sequence
ttctgaagaagatttgATGAGTGATGCAAGTGAC
atcaatttctgttccatTTTATTATTTGTCAGGGGC
attataggatccATGGAACAGAAATTGATTTCTGAAG
tacaatgatatcTCAAACGTTTGAGTCTTCATCTG
ATGAGTGATGCAAGTGACATG
CATGGACCGAGCTCGTAC
tgaagaagatttgtgaGATATCCAGCACAGTGGC
gaaatcaatttctgttcAACGTTTGAGTCTTCATCTG

Liprin-β Co-Immunoprecipitation
Once the tag was added, we amplified the Myc-tagged Liprin-β fragment using primers

containing BamHI and EcoRV restriction digestion sites in order to facilitate cloning into the
pcDNA3.1 vector. After cloning into the expression vector, we also made clones in which we
removed the N-terminal Myc tag and another in which added the tag to the C-terminal. This was
done to ensure that any inhibition of binding to Liprin-α or 14-3-3ζ was not an artefact of
blockage by the N-terminal Myc-tag. The cloning results were validated using DNA sequencing
analysis. A co-transfection with 14-3-3ζ-HA and Liprin-β-Myc or untagged Liprin-β
demonstrated an interaction between both the tagged and untagged Liprin-β constructs and 14-33ζ, but no interaction with Liprin-α (Figure 6).
Knowing that 14-3-3ζ will precipitate with Liprin-α, the lack of interaction demonstrated
in this blot could be an artefact of the endogenous signal being covered up by the strong
fluorescence from the overexpressed Liprin-β proteins. We know from the proteomic analysis
that endogenous Liprin-β interacts with 14-3-3ζ, however we do not see that interaction here
(Lane 8). Lanes 1 and 2 show that endogenous Liprin-β is present in the cell lysate, so the lack of
interaction seen in Lane 8 is likely caused because 14-3-3ζ interacts with so many other proteins
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Figure 6 14-3-3ζ and Liprin-β co-transfection shows interaction. Lysate and HA
tag immunoprecipitate from cells co-transfected with 14-3-3ζ-HA and Liprin-β -Myc
or 14-3-3ζ-HA and untagged Liprin-β show interaction between Liprin-β and 14-3-3ζ.
Immunoprecipitate with the 14-3-3ζ -HA/Liprin-β construct did not co-precipitate
Liprin-α. Lanes 1 and 2 show the presence of endogenous Liprin-β but Lane 8 shows
that there is not enough present to give a strong signal when co-precipitated with 143-3ζ-HA.

that the amount of endogenous Liprin-β pulled down is too little to be observed on a Western
blot analysis

Identification of 14-3-3ζ Binding Motifs
The 14-3-3 family of protein is known to bind other proteins at specific motifs conserved
across species. Analyses carried out using synthetic phosphopeptides revealed that 14-3-3
proteins bind in one of two ways: to canonical motifs such as RSXpSXP and RX(F/Y)XpSXP or
to a phosphorylated residue that is the penultimate amino acid of the C-terminus
(http://scansite.mit.edu).151-152 The pS represents the phosphoserine to which the 14-3-3s bind
and X represents any amino acid24. Though other biding motifs exist, such as a substitution of
phosphothreonine for the serine or even non-motif binding, RXXpSXP is the most common.24
14-3-3 proteins have been shown to bind to two separate proteins, such as in the plant plasma
membrane proton pump where it binds two phosphorylated tails of adjacent subunits.153
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However, 14-3-3s more commonly bind two phosphorylated sites within the same protein in a
cooperative fashion.152, 154 We searched for these motifs within the Liprin-α and -β primary
protein structure to identify the putative 14-3-3ζ binding sites.

2.3.1

Liprin Sequence Alignment
In order to locate the binding sites for 14-3-3ζ on each of the Liprins we carried out an

alignment of amino acid sequences from various eukaryotic species. We identified the conserved
serines and threonines from each alignment and analyzed them for their likelihood of binding to
14-3-3ζ. The possible serine and threonine binding sites were analyzed based on the criteria
found in Table 2.

Table 2: Criteria for 14-3-3ζ Binding Motif Identification
Criterion
Conserved
RXXpS
pSXP
Location

Explanation
It must be conserved across most, if not all, species
It is preceded by an arginine or other positively charged amino acid at least
three but no more than five residues upstream
It is followed by a proline two residues downstream
It cannot be located within the coiled coil region or any of the SAM domains

On Liprin-β we identified one site at S540 that follows the exact RXXpSXP pattern and met all
of the criteria (Figure 7A). None of the serines nor the threonines on Liprin-α followed the
pattern as closely as did Liprin-β, nevertheless four other possible binding sites were identified
that are similar, though not identical, to the 14-3-3ζ binding motif and met the criteria (Figure 7B
and C). In one case, at S239, the serine was followed by a +2 glycine instead of a proline. We
accepted this as a possible motif because both of these hydrophobic residues allow for kinks in
the secondary and tertiary protein structure. The proline has been shown to twist the peptide out
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Figure 7 Locating the putative 14-3-3ζ binding motifs on Liprins. A Alignment of a possible
binding site on Liprin-β at S540 and B on Liprin-α at T387. The red box denotes the conserved
motif containing a pS or pT where 14-3-3ζ could bind. All serines and threonines highlighted
blue. C Table listing all the possible 14-3-3ζ binding sites identified on both Liprins. Column
one indicates the Liprin family member, column two lists the amino acid residue according to the
sequence found on uniprot.org, column three shows the whole motif surrounding the
phosphorylation site.

of the 14-3-3 docking site, a bond rotation that glycine is also capable of supporting due to its
small size.26 The necessity of this twist away from the 14-3-3 dimer remains unknown, but the
substitution of a bulky or charged residue for the proline could disrupt the binding ability.24, 36

2.3.2

Mutation of the Binding Sites
The phosphorylation of 14-3-3ζ motifs is required for binding of 14-3-3ζ to target

proteins. By generating alanine mutations at the serine or threonine, as identified and described
in Figure 7, we created Liprin mutants that cannot be phosphorylated at those residues. The
inability of the mutants to be phosphorylated will allow us to identify the exact phosphoserine or
threonine to which 14-3-3ζ binds on one or both of the Liprins. The sequence of the final Liprinα mutant contained two serines, one with an arginine at the -3 position and the other with a
proline at +2. As either serine could be the target of phosphorylation and 14-3-3ζ binding, both
residues were mutated to alanine.
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The Liprin-β and Liprin-α S530A mutants (denoted with *) were prepared using the
Agilent QuikChange Site-Directed Mutagenesis Kit and primers designed with the
QuikChange® Primer Design Program (Agilent Technologies, California). The remaining three
mutant Liprin-α constructs (denoted with †) were prepared via site-directed mutagenesis using
the Q5® Site-Directed Mutagenesis Kit and primers designed using the NEBaseChangerTM (New
England Biolabs, Massachusetts). The mutant Liprin-β S540A construct is herein referred to only
as Liprin-β SA, as there was only a single mutant construct designed. The four Liprin-α SA
mutants will be identified by the base number of the mutation (i.e. Liprin-α S239A). See Table 3
for a list of the primers used in site-directed mutagenesis, lower case letters indicate the bases
altered to obtain the alanine mutant, results were validated with sequencing.

Table 3: Primers for Site-Directed Mutagenesis
Mutation
*Liprin-β SA
†Liprin-α S239A
†Liprin-α T387A
*Liprin-α S530A
†Liprin-α SS679680AA

Forward Primer
AACAAGAGAACAGCAgcTGC
ACCAAACTTAGC
AAAGAGATCTgCTGATGGTT
CTTTAAG
GAAGGCAGAGgCGCTCCCGG

Reverse Primer
GCTAAGTTTGGTGCAgcTG
CTGTTCTCTTGTT
CCACTCGTGCTTGGTGTA

CTCAGTGTCTGTTGCAGCT
TTTGC
CCCCACTTGGGCgcTGTCCCA AAATCTGGGACAgcGCCCA
GATTT
AGTGGGG
TAGATCTATGgccgCCATTCC AAACGACCAAGATTGTCTAG
CCCC

* Agilent QuikChange Site-Directed Mutagenesis Kit
† Q5® Site-Directed Mutagenesis Kit

Proposed Effects of the Mutant Liprin Constructs
FLAG-tagged Liprin-α (WT, SA, and TA) constructs and Myc-tagged Liprin-β (WT and
SA) constructs were transfected into HEK 293 cells. After a 48-hour incubation period the cells
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were lysed using a 1% Triton-X100 lysis buffer and the proteins co-immunoprecipitated from the
extract. The relative quantity of 14-3-3ζ that co-precipitated with the tagged constructs was
measured by separating the proteins on a Western blot and immunoblotting the precipitate with
anti-14-3-3ζ antibody. Equal loading was determined by immunoblot using an anti-FLAG
(Liprin-α) or anti-Myc (Liprin-β) antibody. The 14-3-3ζ bands from the lanes treated with the
mutant constructs were compared to the WT constructs to determine whether the alanine
substitution disrupted the binding of 14-3-3ζ to the Liprins.
There were two possible outcomes for the binding of 14-3-3ζ to the Liprins mutants: 1)
14-3-3ζ would not IP as strongly with the Liprin S/TA mutant, or 2) minimal to no change would
be seen in the binding of the Liprin mutant when compared to the WT. Results showing the first
outcome would indicate that the mutated residue plays an important role in the binding of 14-33ζ to Liprin. The second outcome would indicate that either 14-3-3ζ does not interact with the
mutated residue or that the binding between 14-3-3ζ and the mutated serine or threonine is a
weak interaction and not necessary to maintain the Liprin-14-3-3ζ interaction.
The outcome would depend on the direct or indirect interaction between 14-3-3ζ and the
Liprin subunits. It could bind to two residues within one of the Liprins or one residue on each of
the Liprins. The 14-3-3ζ interactomics data supports the first hypothesis in that only Liprin-β was
identified as a binding partner. Liprin-α could still be part of the complex but have a direct
interaction with Liprin-β and an indirect interaction with 14-3-3ζ. The second hypothesis is
supported by the data in Figure 5 that illustrates how 14-3-3ζ co-immunoprecipitates from cells
treated with WT Liprin-α-FLAG. Additionally, the alignment data from Liprin-α indicate the
possibility that Liprin-α binds to 14-3-3ζ at one of the amino acid residues listed in Figure 7C.
Though not an exact match to the most common RXXpS/TXP motif, the putative binding sites
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on Liprin-α differ by only a few amino acids. For example, the T387A mutant differs only in the
first amino acid, K, which is the second most common amino acid found at the -4 position.
Furthermore, in the bovine Liprin-α protein, the lysine is an arginine, making it an exact match to
the common 14-3-3ζ binding motif.

Liprin-α Mutants
We first tested the Liprin-α mutants because the Liprin-α construct contained a FLAG tag
to aid in immunoprecipitation. Initially only the S530A mutant was tested, but it showed no
decrease in the amount of 14-3-3ζ binding, the amount of 14-3-3ζ pulled down by the Liprin-α
mutant compared in quantity to that of the wild type (WT) (Figure 8A). Following the S530A
mutation, we mutated the WT Liprin-α construct with three separate sets of primers to obtain the
S239A, T387A, and SS679-680AA mutants. Initially the T387A construct obtained was
truncated (Figure 8B), which did not pull down 14-3-3ζ and only minimally interacted with
Liprin-β so the WT Liprin-α was mutated once again with the Q5® Site-Directed Mutagenesis
kit to obtain the complete, mutated Liprin-α. As seen in Figure 8C and D, none of these
constructs were able to inhibit the co-immunoprecipitation of 14-3-3ζ with Liprin-α. These
results indicate that the interaction between 14-3-3ζ and the Liprin complex occurs either
completely or primarily on Liprin-β.
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Figure 8 Liprin-α SA mutants do not inhibit 14-3-3ζ co-immunoprecipitation. A S530A
mutant is able to co-IP Liprin-β and 14-3-3ζ in comparative quantities, gray arrow indicates
Liprin-β. B SS679-680AA and S239A mutants also pull down 14-3-3ζ and Liprin-β. Orange
arrow indicates Liprin-α, green arrow indicates IgG, and gray arrow indicates Liprin-β. Red *
denotes truncated T387A mutant. C T387A mutant is also able to pull down 14-3-3ζ in quantities
comparative to the WT.

29

Liprin-β Mutants
Initially, the putative 14-3-3ζ interaction with Liprin-β was the more promising of the
two Liprins for two reasons: first, the beta isoform was the only Liprin originally identified in the
interactomics study and second, it contains a conserved 14-3-3 phospho-binding motif at serine
540. To determine whether the Liprin-β SA mutant construct is able to interact with 14-3-3ζ in
vivo, we overexpressed and immunoprecipitated N-terminal Myc-tagged Liprin-β (referred to
herein as Liprin-β-Myc) from HEK 293 cells. The resulting Western blot showed little binding of
14-3-3ζ and no difference between the mutated and WT forms (Figure 9A).

Figure 9 14-3-3ζ, Liprin-α, and LAR do not co-immunoprecipitate with Liprin-β WT or SA
mutants. A Liprin-β containing a Myc tag at the N-terminal transfected into HEK 293 cells only
co-precipitates 14-3-3ζ to a limited degree. B Validation of A indicates that Liprin-β pulldown
does not co-precipitate 14-3-3ζ. Gray arrows indicate Liprin-α bands.

30

Interestingly, neither Liprin-α nor LAR precipitated with Liprin-β. Though we did not
anticipate observing an interaction with LAR, as it directly interacts with Liprin-α, we expected
that the Liprin-α co-precipitation could act somewhat as a positive control. As was discussed in
the previous section, Liprin-β is able to co-precipitate with as Liprin-α-FLAG pulldown.
Previous reports conclude that these two Liprins interact via their C-terminal LH domain, yet we
were unable to observe that interaction in any of our Liprin-β co-IP Western blot analyses, as
will be shown hereafter.
The data shown in Figure 9A seem to contradict our prediction and preliminary data that
indicate a tight interaction between 14-3-3ζ and Liprin-β, though we did observe limited binding
between both the WT and mutant Liprin-β SA constructs. Thinking that perhaps there was an
error in how the co-IP was performed, we repeated the experiment, taking care to follow the
protocol exactly and observed no co-precipitation of 14-3-3ζ with a Liprin-β pulldown (Figure
9B). Additionally, we observed that the Myc IP expressed lower levels than the Myc in the
lysate. This is not normally the case with IPs, but could be due to inaccessibility of the Myc tag
or poor affinity for the antibody expressed on the beads. Though these data oppose our
hypothesis, possible explanations include obstruction of the binding site by the Myc tag, or tooharsh lysis conditions. In order to rule out these as possibilities of interference we carried out
further tests and accounted for these variables, as described in the following sections.

2.6.1

Liprin-β-CMyc
The lack of binding between Liprin-β and Liprin-α/14-3-3ζ could be due to steric

hindrance or occlusion of the binding site by the Myc tag. This was the most likely factor
affecting the binding because, as previously mentioned, the Myc IP was not as strong as the Myc
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in the total lysate. To ensure that the weak or nonexistent interaction between Liprin-β and 14-33ζ was not due to the placement of the Myc tag, we created a Liprin-β construct with a Cterminal Myc tag, hereafter referred to as CMyc. The Liprin-β-CMyc constructs (both WT and
SA) were transfected into HEK 293 cells, co-immunoprecipitated, and run on a Western blot
(Figure 10A). Placement of the Myc tag on the C-terminal did not increase Liprin-α or 14-3-3ζ
binding. Again we saw less Myc in the IP than we did in the total lysate. We also saw limited
pulldown of 14-3-3ζ.
This blot was the most promising, as there appeared to be a stronger interactions between
Liprin-β-CMyc and 14-3-3ζ than between Liprin-β-Myc and 14-3-3ζ. Additionally, the Liprin-β
SA-CMyc appeared to have a weaker interaction with 14-3-3ζ than the WT construct, though we
are unable to conclusively determine that the SA mutation diminishes binding with 14-3-3ζ
because we were unable to validate this in subsequent co-IP/WB analyses (Figure 10B). We
blotted using an antibody specific to the phospho 14-3-3 motif (pMotif) and saw that the
antibody specifically recognized WT Liprin-β but not Liprin-α nor the Liprin-β SA mutant. We
were unable to conclude that the CMyc tag was more effective than the Myc tag on the Nterminus due to our inability to validate the IP.

2.6.2

Liprin-β IP with a Gentle Lysis Buffer
Another possible source of disruption on the interaction between these proteins comes

from the lysis buffer. The results previously described were obtained using a harsh lysis buffer
capable of extracting the membrane-bound LAR from the phospholipid bilayer. In these Liprin-β
immunoprecipitations we are not looking for interaction with LAR (as it binds directly to Liprinα but not Liprin-β) so we carried out a lysis using a different, less harsh, lysis buffer (Figure
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Figure 10 Co-IP of Liprin-β not improved by CMyc tag, lysis buffer, or cell type. A Liprin-β
containing a CMyc tag cells only minimally co-precipitate 14-3-3ζ but not Liprin-α. WT Liprin-β
is recognized by the pMotif antibody (lanes 6 and 7). B A second co-IP and Western blot using
Liprin-β-CMyc showed no transfection. C Cells transfected with WT and Liprin-β SA were
lysed with a gentle lysis buffer, this still does not significantly co-precipitate 14-3-3ζ or Liprin-α
with Liprin-β. D Liprin-β does not significantly co-precipitate 14-3-3ζ or Liprin-α from either
HEK 293 or HeLa cells. Gray arrow indicates Liprin-α immunofluorescence.

33

10C). Despite using a gentler lysis buffer and procedure, 14-3-3ζ only showed minimal coprecipitation (with no difference between WT and SA Liprin-β constructs) and Liprin-α still did
not precipitate with the Myc-tagged Liprin-β. Though minimal amounts of 14-3-3ζ co-IP were
observed, there was no measurable difference between the WT and SA Liprin-β constructs. We
concluded that the lysis conditions between the two buffers had little to no effect on the amount
of Myc-tagged proteins that precipitated with the myc antibodies conjugated to agarose beads
(Figure 10B lanes 5 and 6), nor did it appear to greatly affect the co-precipitation of 14-3-3ζ.

2.6.3

Liprin-β Transfection in HEK 293 and HeLa Cells
In a final attempt to precipitate Liprin-α and 14-3-3ζ with Liprin-β, we transfected both

HEK 293 and HeLa cells with the WT and mutant Liprin-β-Myc constructs and carried out a
lysis, immunoprecipitation, and Western blot analysis. As with the previous attempts, neither of
the target proteins measurably co-precipitate (Figure 10D). Strangely, we were able to observe a
transfection of Liprin-β-Myc into the HeLa cells, but it did not appear in the IP. This leads us to
believe that the IP of Liprin-β with Myc antibodies conjugated to agarose beads is inefficient and
needs to be optimized.

2.6.4

Liprin-β Conclusion
The results of the interactomics study along with research in primary literature lead us to

hypothesize that Liprin-β and 14-3-3ζ would have a strong interaction observable by co-IP and
Western blot analysis. Despite the promising preliminary data we collected using Liprin-αFLAG precipitations and 14-3-3ζ/Liprin-β co-transfections (Figure 6) we were unable to obtain a
valid, replicable co-IP using Liprin-β pulldown using C-terminal and N-terminal Myc tags.
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We chose to use Myc tags on the Liprin-β constructs because our Liprin-α had a FLAG tag
and 14-3-3ζ an HA tag. By tagging Liprin-β with Myc, we would be able to easily distinguish
between all three proteins in the event of a co-transfection. However, the IPs run with Myctagged proteins were inefficient when compared to those done with FLAG- and HA-tagged
proteins. When adding the Myc tag onto the Liprin-β construct, we also made a construct with a
FLAG tag, in case the Myc tag addition did not work properly. However, sequencing data
validated that both constructs had the proper tag added to the plasmid containing Liprin-β. We
determined that the best course of action would be to use the Myc-tagged construct, as it would
help us distinguish exogenous Liprin-β from exogenous Liprin-α or 14-3-3ζ when running cotransfections. The Liprin-β-FLAG construct was never prepared past addition of the tag, though
for future work the FLAG-tagged construct may prove more reliable than the Myc-tagged
Liprin-β. When considering the data from Figure 6 in addition to that presented in Figures 9 and
10, we can see that the Liprin-β-Myc and –CMyc immunoprecipitations are unreliable and the
data inconclusive.

Proposed Mechanism of Liprin-Mediated Metastasis
LAR is a PTPase known to dephosphorylate and interact with proteins that participate in
cell adhesion. The PTPase family is divided into two groups, or subfamilies, consisting of
receptor-like (RPTP) and nonreceptor PTPases, which function by dephosphorylating tyrosylphosphorylated proteins.105-106 Like other RPTPs, LAR possesses a single transmembrane
domain and two intracellular phosphatase domains named D1 and D2.106-107 Unlike most
receptors, ligand binding typically causes inactivation of the RPTPs through dimerization and
inhibition of the active D1 domain by occlusion from the D1 domain of the opposing subunit.108112

The D1 domain is believed to carry out the PTPase activity while the D2 domain typically
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remains inactive but plays a key regulatory role in determining substrate specificity.110, 113-116
Liprin-α binds to the D2 domain of LAR PTPase and is believed to influence which substrates
LAR dephosphorylates when bound to Liprins.117 Published findings and our data indicate that
both 14-3-3ζ and LAR participate in the activation of cell motility. We posit that 14-3-3ζ utilizes
LAR-mediated responses in order to cause an increase in the ability of a cell to migrate. We
propose that 14-3-3ζ plays a scaffolding role with Liprin-β, allowing it to bind Liprin-α, thus
aiding in the localization to the cell periphery where it recruits LAR (Figure 11).

Figure 11 Proposed model of 14-3-3ζinduced and Liprin-mediated metastasis.
The 14-3-3ζ homodimer binds to a
phosphorylated motif on Liprin-β and
putatively on Liprin-α. This interaction
facilitates the recruitment of LAR to the cell
periphery where the complex initiates
metastasis.

Receptor tyrosine kinases (RTKs), the counterpart to RPTPs, act in a manner distinct to
that of RPTPs and are activated through ligand-induced dimerization whereupon each subunit
participates in a trans-phosphorylation of tyrosine residues on the opposing receptor.134 RTKs
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require a triple phosphorylation in order to remain fully active and often are inactivated through
dephosphorylation by either a nonreceptor PTPase or an RPTP. One such RTK substrate of the
LAR PTPase is Ephrin type-A receptor 2 (EphA2),135 also known as epithelial-cell kinase (Eck),
which is a member of the largest family of RTKs.136 Like the other 13 members of the Ephrin
family, EphA2 is membrane-bound and activated by ligands called ephrins, specifically ephrinA. It is believed that the Eph-ephrin interaction and signaling cascade participate in cell motility
by limiting migration through inhibition of integrin-mediated adhesion and spreading, thus
obstructing migration.137-140
We propose that 14-3-3ζ overexpression initiates metastasis by recruiting LAR to the cell
periphery where it can dephosphorylate EphA2, thus inactivating its ability to stabilize integrins
and FAs at the cell surface. This, in turn, triggers the uptake of FAs into the cell causing a loss of
adhesion with the surrounding tissue and ECM, whereupon the cell is free to mobilize and
metastasize to a secondary site within the organism as depicted in Figure 2.

2.7.1

Effect of 14-3-3ζ on Liprin-α-LAR Binding
Considering the role of Liprins in cell motility and given that 14-3-3ζ has been shown to

initiate cell movement and play a part in invasion, the 14-3-3ζ-binding deficient mutants should
disrupt the ability of the cells to metastasize.23, 50-51, 155 However, in order to ensure that the effect
of 14-3-3ζ-Liprin binding plays a role in metastasis, we must measure the ability of these mutant
proteins to interact with LAR. 14-3-3ζ has been shown to interact with Liprin-β, which is known
to bind Liprin-α. Liprin-α, in turn binds LAR and the two have been shown to work
cooperatively to induce cell motility.118-119, 144 It has been shown that the overexpression of full
length Liprin-α is sufficient to drive motility and cause a change in the distribution of FAs at the

37

cell surface, however, truncated versions of the same protein were unable to do so.119
Furthermore, Liprin-α-ΔSAM2 mutants, which lack the domain of the LH region where LAR
interaction occurs, were unable to increase cell spreading of COS-7 cells.118 Considered together,
all of this data leads to the conclusion that Liprin-α plays a role in cell motility but alone is
insufficient to induce it.
As noted above, Liprin-α-ΔSAM2 mutants are unable to bind LAR and many of the
Liprin-mediated effects on cell motility are undetected in cells transfected with ΔSAM2 mutants.
Liprin-α and Liprin-β have been shown to form heterodimers through their C-terminal LH
domains though the exact location of binding remains unknown.117
In accordance with this data and as seen in Figure 12, Liprin-α-ΔSAM2 can still coimmunoprecipitate Liprin-β, indicating that it does not bind to the SAM2 domain. This does not

Figure 12 Liprin-α-ΔSAM2 can bind Liprin-β.
Cells transfected with a mutant form of Liprin-α
lacking the second SAM domain for the LH
region are able to co-IP both Liprin-β and 14-3-3ζ
(lane 4) despite its inability to interact with LAR.
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directly indicate that Liprin-α can bind both LAR and Liprin-β but rather it shows that they do
not bind to the same SAM domain within Liprin-α, which suggests that Liprin-α could possibly
bind to both proteins. Additionally, the results show that Liprin-α binds both Liprin-β and 14-33ζ simultaneously. Previous research insinuates that the formation of Liprin-α/β heterodimers at
the C-terminal LH domain precludes them from binding to other proteins.117 Our results,
however, show that this is not the case, as both 14-3-3ζ and Liprin-β co-immunoprecipitate with
Liprin-α.

2.7.2

Effect of 14-3-3ζ on EphA2 and IRβ Phosphorylation
LAR is a membrane-bound protein tyrosine phosphatase (PTPase) known to

dephosphorylate Insulin Receptor β (IRβ) and EphA2.135, 156 As a phosphatase we can visualize
LAR activity by measuring the amount of phosphorylation on its substrates. Through interaction
with LAR, we believe that Liprins and 14-3-3ζ cause an increase in the dephosphorylation
activity of LAR, though this theory remains to be tested. Additionally, one key question is
whether Liprin interaction with LAR determines what substrates LAR targets. Based on our data
and previously published findings, we posit that Liprin-α increases LAR phosphatase activity
promoting the disassembly of FAs and increase in cell motility.
LAR has been shown to dephosphorylate both pIRβ and pEphA2 at Y1150 and Y930,
respectively. Ideally we would quantify the relative phosphorylation of EphA2 upon
overexpression of 14-3-3ζ, however no antibody exists for pEphA2 at Y930. Before making our
own antibody, we validated our proposed method by observing the phosphorylation of pIRβ.
While HEK 293 cells express pIRα, they do not express significant levels of pIRβ so the
experiments described herein was conducted using HeLa cells.
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Similar to the experiments described above, we carried out a Western blot analysis to
measure LAR phosphatase activity. We used siRNA to knock down 14-3-3ζ, and Liprin-β in
HeLa cells in parallel experiments. After a 12 hour incubation, each plate containing the
transfected or untransfected (control) cells was split into three different plates. Each set of cells
(consisting of one plate split from each of those initially transfected) will receive a different
treatment prior to lysis and analysis. At 36 hours, one set of cells was treated with hypoxia
(hypoxia is herein used to refer to conditions of low glucose and low oxygen, mimicking the
conditions found in the interior of a tumor); at 46 hours, the second set was treated with serum
starvation using EBSS media; the final set received no treatment, mimicking normoxic
conditions. At 48 hours all three sets of cells were lysed and the proteins extracted. The proteins
extracts were run on a Western blot and stained using an immunofluorescent anti-pIRβ
Y1150/1151 antibody (Figure 13).

Figure 13 Phosphorylation of IRβ in HeLa cells remains unchanged by knock
down of Liprin-β and 14-3-3ζ. HeLa cells transfected with siRNA to Liprin-β or
14-3-3ζ and analyzed for phosphorylation of IRβ in conditions of normoxia,
hypoxia, and serum starvation showed no change. Gray arrow indicates
nonspecific band from the anti-IRβ antibody.
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The results of the analysis were inconclusive for a few different reasons: 1) The anti-pIRβ
antibody bound nonspecifically to various proteins, and at the molecular weight corresponding to
pIRβ it showed little to no signal. 2) We were unable to obtain a good knock down of Liprin-β.
3) As this was only a preliminary experiment it lacked the proper controls, such as an antibody
for pIRα. 4) While we used a lysis buffer shown previously to extract membrane-bound proteins,
we cannot say for sure whether it was able to extract pIRβ from the phospholipid bilayer without
causing it to precipitate with the cellular debris. We concluded that using siRNA knockdown of
Liprins or 14-3-3ζ in HeLa cells as described in this section and looking for an effect on
phosphorylation is not the ideal method of evaluating the dephosphorylation of EphA2 by LAR
PTPase.

Thoughts and Conclusions
When synthesizing the data discussed in this chapter and writing out the results, or lack
thereof, in the form of a thesis, it was very disheartening to realize that there is very little to
actually include and even less that I can publish. It appears at first as though very little work was
actually accomplished and in one sense of the word, that is true. Despite the work, thought, and
effort put in by multiple researchers, I can offer no conclusive data. However, to me the work
described in this chapter represents more than just data and conclusions. To me it represents two
years of learning how to work in a lab, read primary literature, and most importantly think like a
researcher. I have come to realize that the bulk of the work is not shown in the concluding
research article, thesis, dissertation, or review, or other publication. Oftentimes the most
important things are those not represented at all: the long hours spent rehashing data and literary
searches when you should have been sleeping, the number of tears shed when your experiment
didn’t work yet again, and the elation of finally getting one tiny thing to work the way it should,
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even if it isn’t necessarily publishable. Like many others involved in research, it’s these moments
and the hunger for knowledge that keep me going despite the odds. I believe that this work with
Liprins and 14-3-3ζ sets forth the foundation for further research and actual conclusive data. In
the following chapter I will discuss a few of the thoughts I have had about the future possibilities
for research into Liprins and 14-3-3ζ and their role in cancer cell metastasis.
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3

FUTURE DIRECTION

Identify the 14-3-3ζ Binding Sites
Despite the work described in Chapter 2, we obtained no conclusive evidence as to where
14-3-3ζ binds to Liprin-β. We also were unable to elucidate whether it bound to Liprin-α, as the
immunoprecipitation data seems to suggest. These results are most likely due to the fact that 143-3 family proteins normally dimerize and bind to two different phosphorylation sites within the
same protein, though occasionally they have been found to bind one phospho-site each on two
adjacent proteins. In order to determine the exact sites of binding on Liprins, we could approach
the problem from one of two ways. The first is to use a proteomic study of one or both of the
Liprins and analyze the data for sites of phosphorylation.
The second is to make larger deletions within the Liprin protein(s) or to mutate two
putative binding sites within the same plasmid. While each method could provide the necessary
information, both have their drawbacks. Truncation or deletion mutations could cause the Liprin
protein to fold in a manner that would disrupt interaction with the kinase and prevent
phosphorylation, which would impede 14-3-3ζ binding. If the kinase were able to gain access,
the misfolding could also prevent 14-3-3ζ itself from binding. Thus, large deletions are a useful
but occasionally inaccurate tool for interaction studies. The problem with making double
mutations of the identified sites is that it involves a large amount of work to obtain the desired
results. For example, if we were to carry out double mutations on the Liprin-a plasmid, it would
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require six new plasmids to be generated. Additionally, that doesn’t account for the 14-3-3ζ
binding occurring between both subunits of a Liprin heterodimer. Despite the drawbacks, these
methods could prove useful in obtaining the 14-3-3ζ-binding-deficient Liprin mutants.

Mimicking Phosphorylation
In our 14-3-3ζ proteomics study where we identified Liprin-β as a novel interacting
partner, we saw that the interaction took place under normoxic conditions and that hypoxia
treatment causes the dissociation of Liprin-β and 14-3-3ζ. This correlates with the LAR activity
assays previously described in which serum starvation causes an increase in phosphorylation of
LAR substrates, indicating that low glucose levels cause a decrease in LAR activity.135, 156 Low
glucose results in a decrease in kinase activity, causing a decrease in Liprin phosphorylation at
the serine residues to which 14-3-3ζ binds.
Once the location of 14-3-3ζ binding has been identified by null mutations in the Liprin
constructs, we can mimic phosphorylation by mutating the serine or threonine residue(s) to
aspartic acid (D) or glutamic acid (E). The D or E mutant mimics phosphorylation by adding a
permanent negative charge to the amino acid residue that it substitutes for, the residue at which
phosphorylation normally takes place. This prevents the protein construct from becoming
dephosphorylated. As the negative charge is necessary for the binding of 14-3-3ζ, this mutation
could act as a positive control for the effect of 14-3-3ζ on the cellular mechanisms and complex
formation described herein.
These phosphomimetic mutants should not require kinase activity in order to bind 14-33ζ and thus these mutant Liprins should interact with 14-3-3ζ without the need for high glucose
concentrations (under hypoxic conditions and serum starvation). For further testing we could
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utilize the phosphomimetic Liprin mutants to increase LAR activity even under conditions of
hypoxia and serum starvation. In cells that overexpress the D/E Liprin mutants, we should see a
decrease in LAR substrate phosphorylation indicating that 14-3-3ζ binding to Liprins is
sufficient and necessary to activate the LAR PTPase.

Liprin-α/β and 14-3-3ζ Complex Formation
After identifying the binding sites through alanine mutations, we will use siRNA to
determine the necessity of Liprin-β in complex formation with Liprin-α and 14-3-3ζ. Originally,
only Liprin-β was identified as a binding partner of 14-3-3ζ, though Liprin-α cannot be ignored
due to its ability to co-immunoprecipitate 14-3-3ζ. However, the strength of the interaction
between Liprin-α and 14-3-3ζ might be weak enough that it was removed in the wash steps prior
to mass spectrometry analysis. If so, Liprin-α could still bind to 14-3-3ζ independently of Liprinβ. By knocking out the endogenous Liprin-β and immunoprecipitating Liprin-α, we can
determine whether the beta subunit is necessary to facilitate the interaction between 14-3-3ζ and
Liprin-α. This will elucidate the function of Liprin-β in complex formation and reveal if it is
required for 14-3-3ζ to carry out its role in Liprin-mediated metastasis. This theory could be
tested by co-transfecting WT Liprin-α with a phosphorylation deficient Liprin-β mutant,
immunoprecipitating Liprin-α, and blotting for 14-3-3ζ. Additionally, this could be validated by
using siRNA to Liprin-β, pulling down Liprin-α, and again blotting for 14-3-3ζ.
As only Liprin-β was found in the proteomics study, we can assume that if Liprin-α binds
14-3-3ζ it does so through a weak interaction. With this knowledge, we would expect to see that
the Liprin-β knockdown causes a decrease in the binding between Liprin-α and 14-3-3ζ. These
results would indicate that, while 14-3-3ζ may still bind to Liprin-α, the stronger and more
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physiologically relevant interaction takes place on Liprin-β. If not, and Liprin-α is capable of
binding 14-3-3ζ in the absence of Liprin-β, then the binding of these two proteins is not
dependent on the interaction between Liprin-β and 14-3-3ζ. From these experiments, the function
of Liprin-β in 14-3-3ζ-Liprin binding will be more clearly defined and will assist in the
experimental design and interpretation of results from the phenotypic characterization as
described below.

Effect on LAR Localization
Liprin-α overexpression has been shown to increase the amount of LAR localized to the
cell periphery. In COS-7 cells under normal conditions and without treatment, LAR is evenly
distributed throughout the cytoplasm, however, upon overexpression of Liprin-α LAR begins to
have a punctate expression pattern within the cell, localized at the periphery.117 Additionally,
truncated LAR constructs that are missing the D2 PTPase domain where Liprin-α binding occurs
also spread evenly throughout the cell and do not congregate at the cell periphery. We posit that
Liprin-α-LAR binding is increased upon overexpression of 14-3-3ζ which facilitates the complex
formation with Liprin-α and LAR and recruitment to the cell periphery.
This could be tested using immunofluorescent staining and microscopy to visualize the
effect of 14-3-3ζ overexpression or knock down on LAR localization. We would expect to
observe a correlation between the level of 14-3-3ζ expression and the localization of LAR. By
imaging 14-3-3ζ and Liprins, we would also expect to observe increased fluorescence correlating
to 14-3-3ζ and Liprin recruitment to the cell edge where they can recruit LAR and initiate its
PTPase activity.
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Focal Adhesion Turnover
Tumors cells develop the ability to spread throughout an organism and avoid
chemotherapy by internalizing FAs, thus releasing from the primary tumor, and subverting
anoikis in order to metastasize. Previous work in non-cancerous cells has shown that full length
Liprin-α interacts with LAR to cause the disassembly of focal adhesions, particularly at the
leading edge of moving cells. Cells use FAs and AJs to maintain contact with the surrounding
cells and ECM in order to facilitate signal transduction, increase stability, and prevent cancerous
cells from metastasizing and forming secondary tumors. We postulate that cancer cells use 14-33ζ-mediated interactions to utilize the inherent cellular mechanism of LAR-mediated
disassembly of FAs to release from the primary tumor and metastasize.
This could be tested using GFP-tagged Paxillin, a component of FAs, and imaging their
turnover at the cell surface through immunofluorescent microscopy. Transfection of GFPPaxillin could be done in MDA-MB-231 cells, a breast cancer cell line known to have high
levels of cell motility, in the presence and absence of 14-3-3ζ. Live cell fluorescence microscopy
could be utilized to visualize where in the cell the FAs congregate. We anticipate that 14-3-3ζ
overexpression will increase the GFP-Paxillin, and thus FA, turnover in cells. Conversely, the
cells in which 14-3-3ζ is knocked down will show more stable levels of GFP-Paxillin at the cell
surface. In the MDA-MB-231 breast cancer cell line that has increased cell motility, we
anticipate that 14-3-3ζ will cause the GFP-Paxillin to localize to the leading edge and show
increased turnover rates.
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Liprin-Mediated Metastasis in Breast Cancer Cells
The experiments described above elucidate how 14-3-3ζ affects some of the hallmarks of
cell motility, such as FA turnover and LAR localization to the cell periphery. However, the
results of these tests do not provide conclusive evidence that the Liprin-14-3-3ζ interaction
causes an increase in cell motility or, in the case of breast cancer cells, metastasis. In order to
more clearly define the role of this interaction in metastasis, the 14-3-3z and Liprin binding
could be disrupted in the highly metastatic breast cancer cell line MDA-MB-231 by
overexpressing Liprin SA or TA mutants. In a similar fashion, HEK 293 cells that do not
normally metastasize could be transfected with 14-3-3ζ and WT Liprins. The live cell imaging of
lamellipodia formation as well as motility and movement could be done in both cell lines
following a procedure similar to that described in Astro et al, 2011.144
14-3-3ζ has been shown to correlate with increased metastasis in cancer cells and is used
by some as a marker for patient prognosis and likelihood of cancer recurrence. We expect that
the untreated MDA-MB-231 cells will show a higher level of lamellipodia formation as well as
motility. When treated with Liprin SA or TA mutants, the amount of movement as well as the
lamellipodia formation should be decreased due to the lack of antagonizing effect of 14-3-3ζ via
the Liprin pathway. By overexpressing 14-3-3ζ and Liprins in HEK 293 cells and plating them
on a surface that allows for movement, we expect to see an increase in motility, even in these
cells known to be non-invasive. This would indicate that 14-3-3ζ and Liprin overexpression is
sufficient to induce metastasis.
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